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Abstract
Background: Rifampicin resistance is a risk factor for poor outcome in tuberculosis. Therefore, we sought to
describe the characteristics and management of Rifampicin monoresistant (RMR) tuberculosis (TB) in France.
Methods: We conducted a retrospective cohort analysis in 2012 on RMR TB patients diagnosed in France between
2005 and 2010 by using a national laboratory network. A standardized questionnaire was used to collect basic
demographic data, region of birth, history of TB, HIV-coinfection, alcohol use, and antituberculosis treatment.
Outcome was assessed after at least 18 months of follow-up.
Results: A total of 39 patients with RMR TB were reported (0.12% of all TB cases). Overall, 19 (49%) had a previous
history of treatment, 9 (23%) were HIV-coinfected, and 24 (62%) were smear-positive. Patient with secondary RMR
were more likely to have alcohol abuse (P = 0.04) and HIV-coinfection (p = 0.04). Treatment outcome could be
assessed for 30 patients, the nine others being dead or lost to follow-up. A total of 20 (67%) of the 30 assessed were
cured, 3 (10%) died, 3 (10%) relapsed, and 4 (13%) were lost to follow up. Four (13%) received less than 6 months of
treatment, 3 did not have any modification of the standardized regimen, 13 (43%) received fluoroquinolones, 4 (13%)
aminoglycosides, and 8 (26%) a combination of both.
Conclusions: RMR TB is a rare disease in France, and its management was heterogeneous. The lack of treatment
standardization may be a consequence of low expertise and may lead to the unsatisfactory low success rate.
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Background
The main risk factor for antituberculosis drug resistance
is a previous treatment by antituberculosis drugs, and
acquired resistance is a direct and almost immediate
indicator of tuberculosis (TB) control program perfor-
mance [1,2]. Acquisition of drug resistance by M. tubercu-
losis is a stepwise process because no single biochemical
mechanism leads to cross-resistance amongst first line
drugs. Therefore, multidrug resistance, i.e. resistance to at
least isoniazid and rifampicin, arises after acquisition of
either isoniazid or rifampicin resistance followed by acqui-
sition of resistance to the companion drug. Isoniazid-
resistant, rifampicin-susceptible strains are quite common.
Indeed, prevalence of isoniazid mono-resistance is around
5% among new TB cases in France and in most Western
Europe, and is by far more frequent in previously treated
cases [3]. On the opposite, rifampicin mono-resistance
(RMR) is very infrequent, and accounts for only a few
cases each year in most countries. RMR has been associ-
ated with a previous history of TB treatment and HIV-
coinfection [4,5]. Both types of mono-resistance represent
a first step toward MDR, and therefore should be ma-
naged carefully [6]. While the impact of isoniazid mono-
resistance on patient’s outcome has been re-analyzed
recently [7-9], impact of rifampicin mono-resistance,
which may be more problematic, is not well described
[10]. Noteworthy, the management of patients with RMR
TB is not fully standardized. International guidelines offer
different options and no clinical trial have been conducted
with the most recent drugs. For instance, in 2003, accord-
ing to the American Thoracic Society, it is recommended
to treat RMR TB by a prolonged association of three anti-
tuberculosis drugs during nine (isoniazid, pyrazinamide
* Correspondence: jerome.robert0@upmc.fr
1Sorbonne Universités, UPMC Univ Paris 06, U1135, Centre for Immunology
and Microbial Infections, team 13, F-75013 Paris, France
3INSERM, U1135, Centre for Immunology and Microbial Infections, team 13,
F-75013 Paris, France
Full list of author information is available at the end of the article
© 2014 Meyssonnier et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Meyssonnier et al. BMC Infectious Diseases 2014, 14:18
http://www.biomedcentral.com/1471-2334/14/18
and streptomycin) to twelve (isoniazid, pyrazinamide, and
ethambutol) months. It is also proposed to strengthen
these regimens by the addition of a fluoroquinolone for
patients with more extensive disease [11]. Although the
treatment of RMR TB has not been specifically addressed
in the last WHO guidelines, [12], it was specified in the
2008 version that RMR TB should receive a fluoroquino-
lone in place of rifampicin in association with isoniazid
and ethambutol and addition of pyrazinamide during first
2 months for a duration of 12–18 months, with addition
of an injectable in patients with extensive disease [13].
Finally, very recently, the IUATLD recommended trea-
ting RMR TB similarly as MDR TB [14]. Currently, no
recommendations are available in France for RMR TB
management.
In order to evaluate the magnitude of RMR in France,
and to describe treatment’s regimens received and out-
come, we conducted a nationwide retrospective study on
RMR TB diagnosed between 2005 and 2010.
Methods
RMR cases were reported yearly from 2005 to 2010
through a retrospective questionnaire by the national
network of all microbiologists from hospital and private
laboratories performing culture for mycobacteria and co-
ordinated by the National Reference Center (NRC) [15].
A RMR strain was defined as a strain resistant to ri-
fampicin and susceptible to isoniazid, on the basis of
first-line drug susceptibility tests (DST) analysis on solid
or liquid media performed by reporting laboratories. For
each RMR case reported during the study period, a
comprehensive questionnaire was sent for the purpose
of the study to the laboratory and the clinician in
charge to collect patients and disease characteristics,
HIV co-infection, and prior history of treatment with
anti-tuberculosis drugs. In addition, microbiological re-
sults, antituberculosis drugs regimens, compliance, and
outcome (death, lost to follow-up, cure and relapse) were
collected. All data were extracted from medical records
and no personal identifiers were recorded. Therefore, the
study did not require approval by an ethical committee
nor by the electronic data protection commission. The
molecular analysis of the mechanism of rifampicin re-
sistance has been performed either locally or by the
NRC by using the GenoType® MTBDR or MTBDR
plus assays (HainLifeScience GmbH, Nehren, Germany)
or in home sequencing methods [16]. Because it is a retro-
spective study, strains were not available for complemen-
tary analysis.
Duration of treatment was divided into four cat-
egories: < 6 months, 6 to < 9 months, 9 to 12 months
and more than 12 months. All quinolones (ofloxacin,
ciprofloxacin, moxifloxacin, and levofloxacin) were
grouped into a single category. All aminoglycosides
(amikacin and streptomycin) were also grouped into
a single category.
Only those patients treated for more than one month
before outcome were included in the outcome analysis.
Kaplan-Meier analysis was performed to analyze the cu-
mulative probability of unfavorable outcome, i.e. failure,
in new and previously treated patients by using time
from TB treatment initiation to the last medical visit. Pa-
tients with unknown outcome before the end of the pro-
grammed treatment duration, i.e. lost to follow-up, those
with relapse, and deceased patients were considered as
failure. Therefore, no patient was censored. Categorical
variables were compared by using the χ2 test. P-values
are two-tailed and p < 0.05 was considered statistically
significant. Data were analyzed by using Stata 11 (Stata
Corp, College Station, TX, USA).
Results
A total of 49 TB patients with RMR were reported to
the network between 2005 and 2010. Among all re-
ported cases, 6 were excluded because of missing data
precluding any analysis and 4 because of duplicate dec-
laration. Consequently, 39 cases of RMR tuberculosis
were included. By definition, all strains were resistant to
rifampicin and susceptible to isoniazid. Results of mo-
lecular analysis of rifampicin resistance were available
for 21 of the 39 RMR strains. The mutations identified
in rpoB were Ser531Leu (n = 9), His526Tyr (n = 4),
His526Asp (n = 2), Leu533Pro (n = 2) and Asp516Val
(n = 1). In addition, 3 strains had non-identified muta-
tions (no hybridization with the wild-type and mutation
probes), and therefore were considered as having a mu-
tation not identified by the mutations probes. No add-
itional molecular analysis was performed on the three
latter strains. For the 18 remaining strains, molecular
analysis was not performed.
The total number of RMR TB reported each year dur-
ing the study period varied between 3 and 11 cases, ac-
counting for a mean annual RMR rate of 0,12% among
all culture-positive TB diagnosed by the network. The 39
cases were reported by a total of 27 laboratories from 8
of 22 metropolitan regions and from two out of four
overseas French departments.
Among all patients, 20 (51%) had no recognized
history of TB treatment, and 19 (49%) reported a prior
history of treatment (Table 1). The previous antitubercu-
losis regimens could be fully assessed in only 12 of the
19 previously treated patients. All 12 former patients
had received rifampicin-containing regimens, and 8 com-
pleted their treatment. Two patients, who were homeless
and alcohol addicts, stopped the treatment by their own
and went back to hospital because of clinical relapse; the
two latter were opposed to any care. Of interest, 10 of the
12 patients reported frequent treatment interruptions.
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Among all cases, 19 (49%) were male, with a median
age of 43 years (interquartile range: 29–58), 18 (46%) were
born outside of France. Among patients with no his-
tory of treatment, 12 (60%) were born outside of France as
compared to 6 (31%) among those with prior treatment
history (P = 0.07).
Fourteen (36%) were living in collectivity or had a pre-
carious social situation. Four had an immune-compro-
mising disease (diabetes, corticosteroid therapy). Of note,
5 (13%) had contacts with relatives (grand-mother, wife,
children) treated for TB, including two treated for RMR
TB. Genotyping, which confirmed cross-transmission, was
performed for only one couple of cases.
HIV co-infection and alcohol addiction were signi-
ficantly more frequent in previously treated patients
(37% and 37%, respectively) than among patients with
no history of treatment (10%, P = 0.04; and 10%, P = 0.01,
respectively).
A majority of patients (61.5%) had pulmonary TB, and
this proportion was not significantly different according
to HIV status. Sputum smear-positive TB was signifi-
cantly more frequent among previously treated patients
than among others (89% vs 35%, P < 0.001). All but one,
were infected by Mycobacterium tuberculosis strains,
and the remaining patient was infected by M. bovis.
Overall, one strain was resistant to ethambutol, and two
were resistant to streptomycin. Susceptibility tests re-
sults to quinolones and amikacin have been performed
at the NRC for 20 (51%) strains, among which 2 were re-
sistant to quinolones (the M. bovis strain from a patient
with secondary RMR, and one from a patient with pri-
mary RMR), and none to amikacin.
Data about treatment and outcome were not available
for three patients. In addition, two patients were lost to
follow-up or died before treatment initiation, three were
lost to follow-up during the first month of treatment
course and one died before availability of susceptibility
tests. Finally, treatment outcome was assessed for 30 of
the 39 patients (Table 2).
At the time of TB diagnosis, and before susceptibility
tests results, 25 (83%) out of the 30 patients received
rifampicin-containing regimens. The five remaining pa-
tients did not receive rifampicin because of suspected
resistance according to previous treatment history or
availability of first line susceptibility tests from other
countries or contact. Among them, 3 received a com-
bination of moxifloxacin and aminoglycoside with the
three other first line drugs (one receive isoniazid only
after availability of susceptibility tests), one moxifloxa-
cin combined to isoniazid and pyrazinamide, and one
amikacine along with other first line drugs.
Four (13%) patients received less than 6 months of
treatment, including two because of death at three and
five months of treatment, and two that stopped their
treatment after 3 months and were lost to follow-up, in-
cluding one which eventually relapsed the following
year. For the 26 remaining patients, the duration of
treatment spanned from 8 months (n = 2, 7%), 9 to
Table 1 Characteristics of the 39 patients with rifampicin
monoresistant tuberculosis reported in France between
2005 and 2010
Characteristic Total History of
treatment
P value
N(%) No N(%) Yes N(%)
Total patients 39 (100) 20 (100) 19 (100)
Male 19 (49) 8 (45) 11 (58) 0.63
Age median [IQR] 43 [29–58] 38.5 [24.5–58] 44 [36–58]
≥ 40 years old 21 (54) 10 (50) 11 (58) 0.62
Foreign born patients 18 (46) 12 (60) 6 (31) 0.07
If yes, year of arrival in
France:
< 5 years 10 8 2
5–10 years 4 2 2
≥ 19 years 3 1 2
NA 1 1
Travel ≤ 2 years before
diagnosis:
Yes 10 (26) 7 (35) 3 (16) 0.38
No 25 (64) 11 (55) 14 (74)
NA 4 2 2
Social disadvantage 9 (23) 3 (15) 6 (30) 0.12
Collectivity 5 (13) 3 (15) 2 (10) 0.31
History of tuberculosis
before diagnosis:
20 (51) 1* (5) 19 (100)
< 5 years 15 15
> 20 years 3 1* 2
NA 2 2
History of:
-Incarceration 0 0 0 -
-Intravenous drug user 3 (8) 1 (5) 2 (10.5) 0.40
-Tuberculosis exposure 5 (13) 4 (20) 1 (5) 0.38
-Alcohol use 9 (23) 2 (10) 7 (37) 0.04
-Immunosuppression 4 (10) 3 (15) 1 (5) 0.32
HIV co-infection 9 (23) 2 (10) 7 (37) 0.04
Site of tuberculosis:
-Pulmonary 24 (61.5) 12 (60) 12 (63) 0.94
-Extra-pulmonary 8 (20.5) 4 (20) 4 (21)
-Pulmonary and
extra-pulmonary
7 (18) 4 (20) 3 (16)
Smear-positive 24 (62%) 7 (35%) 17 (89%) <0.001
IQR: inter-quartile range; NA: not available.
*: This patient did not receive any treatment.
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12 months (n = 13, 44%) patients, and 11 to 24 months
(n = 11, 37%). Overall, good adherence to TB treatment,
i.e. no interruption of > 1 week, was reported in 20
(74%) patients.
When susceptibility tests results to first line drugs
were available, 3 patients did not have any modification
of the rifampicin-containing regimen. Among these
three patients, two were considered as cured after 9
months of treatment (two months of standard four-drug
regimen and 7 months of rifampicin and isoniazid) with
more than 2-year follow-up. The third patient, who had
a Kaposi sarcoma related to HIV-coinfection, died after
9 months of standard treatment.
Thirteen (43%) patients received fluoroquinolone-
containing regimens without aminoglycoside, 4 (13%)
received amikacin-containing regimens without fluoro-
quinolone, and 8 (26%) received regimens containing both
fluoroquinolones and amikacin. Among the 21 patients
who received at least one month of fluroquinolone, 15
(71%) received moxifloxacin. Patients with extrapulmo-
nary TB (n = 10), and those with a history of antitubercu-
losis treatment (n = 14) were not more likely to receive
fluoroquinolones (70% and 79%, respectively) than pa-
tients with only pulmonary TB (n = 20, 70%; P = 1.0) or
with no history of antituberculosis treatment (n = 16, 63%;
P = 0.34). On the opposite, the 18 with smear-positive TB
were more likely to receive fluoroquinolones than the 12
patients with smear-negative TB (89% versus 30%, respec-
tively; P = 0.003).
A total of 20 patients (67% of the patients with follow-
up, but 51% of all RMR patients) were considered as
cured or completed treatment with clinically favorable
outcome at the last registered visit (18 months of me-
dian follow-up after onset of TB treatment), including
13 who received fluoroquinolones, 9 who received ami-
noglycosides, and 19 with a duration of treatment of at
least 9 months. Outcome was considered as unfavorable
for the other ten (33%) followed patients (3 relapses, 4
lost of follow-up, and 3 deaths). The outcome was less
favorable for those with a previous history of treatment
(50%) than for new patients (19%) (Figure 1), but the
difference was not statistically significant (p = 0.14, log-
rank test). No statistically significant difference was ob-
served according to HIV status (data not shown).
Table 2 Characteristics of treatment regimens of the 30 rifampicin monoresistant tuberculosis patients included in the
outcome analysis by outcome and for those with extrapulmonary tuberculosis
Treatment characteristic Total patients
(n = 30)
Outcome Extrapulmonary








Total duration of treatment
< 6 months 4 (13%) 1 21 11 2
6 to <9 months 2 (7%) 1 11 0
9–12 months 13 (44%) 92 2 21 7
13–24 months 11 (37%) 102 1 1
Total FQuinolones (no AG) 13 (43%) 7 (35%) 1 (25%) 3(100%) 2 (66%) 6 (60%)
1–3 months 3 1 32 2
4–6 months 1 0
> 6 months 9 7 21 4
Total AG (no FQuinolone) 4 (13%) 3 (15%) 1 (25%) 0 0 1 (10%)
1–3 months 3 2 1 1
> 3 months 1 1 0
FQuinolones and AG* 8 (26%) 6 (30%) 1 (25%) 0 1 (33%) 1 (10%)
Duration of AG
1–3 months 6 53 11 0
> 3 months 2 1 1 1
Duration of FQuinolones
1–3 months 2 21 1
4–6 months 1 1 0
> 6 months 5 41 11 0
Numbers in indices indicate the number of HIV co-infected patients for the category, if any.
FQuinolones = any fluoroquinolone, AG = any aminoglycoside.
*Duration of the combination of at least one month.
°: 5 pulmonary and extrapulmonary tuberculosis and 5 with only extrapulmonary tuberculosis.
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Patients treated with fluoroquinolones for at least 6
months were slightly more likely to have favorable out-
come (11 out of 14 cases, 78%) than others (9 out of 16
cases, 56%) but the difference was not statistically sig-
nificant (p = 0.20).
Discussion
The impact and the management of RMR TB have not
been deeply studied as compared to MDR TB, which is
well known to be associated with poor TB outcome [1].
We evaluated the characteristics and the management of
RMR TB in France over a 6-year study period. We con-
firmed that RMR is a rare event (0.12% of all culture-
positive cases). We report a high proportion of RMR
among new patients. Finally, we showed that RMR TB
management was quite heterogeneous in France during
the study period, with neither standardized drug regimen
nor duration of treatment, and that the outcome was
not very satisfactory.
In France, RMR TB is a rare event. The overall ob-
served proportion of 0.12% is similar to those reported
in countries with similar epidemiological profile of TB
such as Western Europe. In 2010, RMR TB accounted
for 0.3%, 0.3%, and 0.1% of primary TB cases, and 1.9%,
0%, and 0.2% of secondary TB cases in Germany, United
Kingdom, and Poland, respectively [17]. However, RMR
seems to be higher in high incidence countries such as
Zambia in 2006 where it reached 1.3% among new cases,
and 3.2% among previously treated cases [18]. There is
an alarming report from South Africa regarding a rise in
RMR TB among HIV-coinfected persons [19]. It has
been previously reported that RMR was associated to
HIV-coinfection [5,20-23]. Our report and the one from
South Africa confirm this association [19]. Indeed, the
23% of HIV-positive patients in the current study con-
trast with the one reported among all patients in France
(10%) and among MDR TB cases reported in 2009 (9%)
[5,24]. The reasons for such an association have not
been fully clarified. Exposure to RMR sources in health
care facilities or at home may explain primary RMR.
Cross transmission has been demonstrated in 13% of
the cases in the USA, and family exposure is likely or
confirmed in two (10%) of the 20 primary cases in our
study [4].
Alcohol abuse has been already associated with RMR
TB [19]. In the present study, it has been linked to RMR
in previously treated cases in univariate analysis. It is
likely that it is an indirect measure of unstable social
background and bad compliance leading to selection of
resistant mutant during treatment [25-27]. Interference
with pharmacokinetics of antituberculosis drugs has been
suggested but, to date, this has not been confirmed [28].
We report a high heterogeneity in RMR TB manage-
ment in France. Many reasons may lead to this worrying
situation. First, it is a rare disease and therefore, it is
difficult to build an expertise for most clinicians. To
reinforce this issue, cases were disseminated throughout
the French territory, and no single referral team has
been identified. Second, guidelines regarding RMR TB
available at the time of the study offer many treatment
options making standardization more difficult [11-14].
However, the IUATLD guidelines published in 2013 after
the completion of our study recommend treating RMR
TB similarly as MDR TB [14]. A large proportion of
strains were not sent to an expert laboratory for testing
against second line drugs making the choice of treat-
ment much more random although very few additional
resistance were observed among tested strains. It has
Figure 1 Patients’ survival (Kaplan-Meier analysis) according to previous history of treatment.
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been proven that treatment of RMR TB can be very
successful if aminoglycosides and fluoroquinolones are
used, along with a prolonged treatment duration [29].
Finally new drugs recently approved to treat MDR TB
may improve the outcome. Therefore, we suggest that
RMR TB management in France follows the same prin-
ciples as those currently accepted as good practices for
the management of MDR TB [12]. We implemented
such a strategy after the dramatic observation of a low
success rate in the treatment of MDR TB cases in the
1990s [30,31]. This strategy was focused only on MDR
TB but overlooked RMR TB. Laboratories should be
aware about the requirement to confirm rifampicin resist-
ance and isoniazid susceptibility, as well as to determine
susceptibility to second-line drugs in case of rifampicin
resistance. In addition, the treatment standardization by
referring to an expert team, as recommended for the ma-
nagement of MDR TB, should improve the RMR TB out-
come. Finally, it is likely that the use of rapid molecular
evaluation of rifampicin resistance has spread in France
since the start of the study in 2005. This should be
confirmed and the interest of such test should be re-
emphasized [12].
Two (10%) of the 20 strains with rpoB mutations had
a Leu533Pro genotype that confers a low-level of rifam-
picin resistance (minimal inhibitory concentration, MIC
of 0.5 mg/L) [32]. The peak to serum concentration of
rifampicin being close to 10 mg/L, rifampicin could retain
some activity against such strains [33]. The recent interest
of the moxifloxacin use against strains with low-level of
fluoroquinolone resistance reinforces this hypothesis [34].
Consequently, we suggest that MIC determination should
be performed for all strains with a Leu533Pro genotype or
for strains with mutations with unknown impact on the
rifampicin MIC level.
Our study is an observational study with a limited
number of cases. Therefore, it is lacking of power to
draw definite conclusion regarding the interest of fluoro-
quinolones or aminoglycosides in place of rifampicin in
combination with isoniazid for the treatment of RMR
TB as well as the role of characteristics such as HIV co-
infection of previous treatment history. The interest
fluoroquinolones and aminoglycosides has been reported
for MDR TB [27,28,35]. Because the present study is ob-
servational, the choice the two latter drugs, or of the
duration of the treatment may be linked to variables not
fully assessed such as severity of illness or co-morbidities.
Consequently, we did not attempt to identify treatment
regimens significantly associated with a favorable outcome
because of potential biases. Pooling data from different
countries and different observational studies will make it
easier to evaluate the relative interest of each drug and of
the optimal duration of the treatment as it has been re-
cently reported for MDR TB [36].
Conclusion
In conclusion, the present study alerts on the heteroge-
neity of the management of RMR TB in a low incidence
country. Despite its paucity, RMR should be carefully
managed because it has a worse outcome than pan-
susceptible TB, and it is a first step toward MDR TB.
Efforts should be driven on comprehensive drug sus-
ceptibility testing, and standardized management. The
implementation of a prospective cohort with a register will
help in the evaluation of the program.
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